skip to primary navigationskip to content

Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

last modified Oct 05, 2016 03:46 PM
Amadeus Capital Partners, the global technology investor, has made an early-stage investment of £1.5 million in ideaSpace alumni Healx, a Cambridge based healthcare company that seeks new uses for existing drugs in the fight against rare diseases.
Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

Dr Tim Guilliams, Healx CEO

Healx, founded and based in Cambridge, operates in the fast-growing drug ‘repurposing’ sector. The company uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis, to identify novel drug applications for rare diseases that afflict some 350 million people worldwide. Their unique model engages directly with patient advocacy groups, allowing them to lead the way in personalised healthcare for rare diseases.

Hermann Hauser, Partner and co-Founder of Amadeus Capital Partners, said, “Healx has taken advances in machine learning, data mining and analytics and combined them with deep pharma and life sciences expertise to address a growing need in the healthcare sector. With huge pressure on R&D budgets, drug repositioning will be essential in the fight against rare diseases. With this investment, Healx will take up a leadership position in the drug repurposing sector, expected to be worth over $31 billion by 2020.”

Healx has a scalable technology platform which allows it to match potential treatments to rare conditions and patients. Thanks to its data mining approach, the company aims to complete its drug repurposing studies within six months, much faster than historical literature-based studies.

While there are around 8,000 rare diseases – disorders affecting fewer than 1 in 2,000 people in Europe – only about 500 have a cure. Many are linked to genetics and children account for some 75% of identified cases. Healx has won contracts from major medical foundations in the US and Europe to find drug candidates to treat conditions including childhood diseases, Barth syndrome and Fragile-X.

Sales of ‘orphan’ drugs designed to treat a specific rare condition have been growing following changes in regulation and tax incentives in the US, with the market forecast to reach $178 billion in 2020. However, as only a small proportion of the population is affected by a particular rare disease, the justification for investing large sums in clinical trials remains a barrier to innovation.

Tim Guilliams, Chief Executive, Healx, commented: “Studies into rare medical conditions have long failed to receive adequate funding. By repurposing existing drugs to combat rare diseases, Healx is able to find potential treatments at a fraction of the cost and in a much shorter timeframe than developing a new drug. With this investment, Healx will have the resources to expand our technology platform and accelerate our drug review process to find treatments to many more devastating illnesses.”

To read more information, click here.

RSS Feed Latest news

Spotlight on Mursla

Feb 03, 2019

Cancer is one of the most challenging global issues an entrepreneur could choose to tackle. But Pierre Arsène and Victor Serdio are doing just that with their company Mursla. Based at ideaSpace West, Mursla is developing a breakthrough technology for early cancer detection using liquid biopsies, offering a less invasive and more responsive approach to diagnosis, treatment and cure. To mark World Cancer Day on the 4th February, we asked Pierre to explain more about Mursla and the bold ideas and enthusiasm driving this bright company.

LESSONS FROM A FOUNDER: What's Your 2019 Startup Goal?

Jan 30, 2019

For many of us, a new year often starts with an optimistic resolution to change – join the gym, write a book, travel perhaps. But if you’re running a startup, January is a great time to assess your company’s development and set fresh goals for the coming year. We asked four founders at ideaSpace to reflect on progress and share their area of focus for 2019.

GeoSpock Lands £10 Million in Additional Funding 

Jan 09, 2019

ideaSpace alumni and extreme data specialists, GeoSpock, have secured an extra  £10 million in funding. The latest round was led by Cambridge Innovation Capital (CIC) jointly with Parkwalk Advisors and Japanese firms Global Brain and 31Ventures. Japanese data tech company KDDI Supership joined as a strategic investor. Investment was also secured from existing investor, Jonathan Milner.

A Breath Test Could Detect Early Cancer Signs

Jan 06, 2019

CRUK and ideaSpace City members, Owlstone Medical, have launched a new trial to discover whether it's possible to detect early stage cancer symptoms from a person's breath.

Petagene secure $2.1 Million in Funding 

Jan 03, 2019

2019 is off to a great start for the Petagene team who have been awarded $2.1 million in additional funding. The latest round was lead by U.S. venture firm Romulus Capital, with collaboration from other unnamed investors in London and Silicon Valley, bringing the total funding awarded to $3.2 million.

View all news